GeneTex
United States (US)

KCNQ1 blocking peptide

Cat No. GTX88458-PEP

Application ELISA, Apuri, Blocking
Species Human
APPLICATION

Specificity/Sensitivity

The peptide was used in the production of GTX88458.
PROPERTIES

Form

Lyophilized powder

Buffer

Lyophilized from 5% (v/v) acetonitrile/H₂O. Reconstitute pellet in 200μl distilled water to obtain a 0.5mg/ml peptide solution.

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Region/Sequence

C-EQLTVPRRGPDEGS

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Potassium Voltage-Gated Channel Subfamily Q Member 1,Atfb1,Atfb3,Jlns1,Kcna8,Kcna9,Kvlqt1,Kv1.9,Kv7.1,Lqt,Lqt1,Rws,Sqt2,Wrs,Kcnq1

Background

This gene encodes a voltage-gated potassium channel required for repolarization phase of the cardiac action potential. This protein can form heteromultimers with two other potassium channel proteins, KCNE1 and KCNE3. Mutations in this gene are associated with hereditary long QT syndrome 1 (also known as Romano-Ward syndrome), Jervell and Lange-Nielsen syndrome, and familial atrial fibrillation. This gene exhibits tissue-specific imprinting, with preferential expression from the maternal allele in some tissues, and biallelic expression in others. This gene is located in a region of chromosome 11 amongst other imprinted genes that are associated with Beckwith-Wiedemann syndrome (BWS), and itself has been shown to be disrupted by chromosomal rearrangements in patients with BWS. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Aug 2011]

Research Area

Package List Price ($)
$ 239